Minerva Neurosciences, Inc is a biotech company based in Burlington, MA, specializing in the development of innovative treatments for central nervous system disorders. With a strong focus on clinical development, their expertise lies in designing trials with clinical endpoints directly related to patient benefit. Their pipeline includes product candidates such as Roluperidone, MIN-101, MIN-301, and Seltorexant, targeting diseases like schizophrenia and Parkinson's disease.
Driven by a commitment to patient-focused care, Minerva Neurosciences aims to recruit patients who will benefit from their treatment options. Their dedication to clinical expertise and innovation sets them apart in the field, as they strive to make a positive impact on the lives of individuals suffering from neurological disorders.
Generated from the website